{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T22:57:14Z","timestamp":1772060234153,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an immune-mediated polyneuropathy, which is characterized by areflexia and ascending paresthesia which can progress to a respiratory failure. Certain conditions, such as vasculitis and heavy metal and drug toxicity, may have misleadingly similar clinical presentation to GBS. We describe a case of a patient with cystic fibrosis and intravenous colistin-induced neurotoxicity mimicking GBS. The patient had used inhaled colistin on five occasions with no adverse effects, however, developed symptoms on the second day of intravenous treatment. Overlapping findings between immune-mediated polyneuropathy and drug-induced neurotoxicity include limb paresthesia and decreased reflexes. Perioral tingling, however, is a common presentation of colistin-induced neurotoxicity, and therefore, is an important differentiating factor. Early diagnosis prevents further neurologic decline, extensive unnecessary workup and potentially harmful incorrect management.<\/jats:p>","DOI":"10.1093\/omcr\/omab080","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:59:35Z","timestamp":1631530775000},"source":"Crossref","is-referenced-by-count":11,"title":["Colistin neurotoxicity mimicking Guillain-Barr\u00e9 syndrome in a patient with cystic fibrosis: case report and review"],"prefix":"10.1093","volume":"2021","author":[{"given":"Celeste","family":"Camargo","sequence":"first","affiliation":[{"name":"International Observer at Mayo Clinic Department of Neurology, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tathagat","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA"},{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA"},{"name":"Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A","family":"Jackson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Padro","sequence":"additional","affiliation":[{"name":"Department of Transplantation, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W David","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA"},{"name":"Department of Neurologic Surgery, Mayo Clinic, Jacksonville, FL, USA"},{"name":"Department of Neurology, Mayo Clinic, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"2021091310552297300_ref1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"2021091310552297300_ref2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.nrl.0000117821.35196.0b","article-title":"Variants and mimics of Guillain Barre Syndrome","volume":"10","author":"Levin","year":"2004","journal-title":"Neurologist"},{"key":"2021091310552297300_ref3","volume-title":"Neuromuscular Disorders in Clinical Practice","author":"Hargrave","year":"2014"},{"key":"2021091310552297300_ref4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1472-6963-11-101","article-title":"Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome","volume":"11","author":"Winters","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"2021091310552297300_ref5","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s40262-017-0561-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of colistin","volume":"56","author":"Gregoire","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2021091310552297300_ref6","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-210787","article-title":"Colistin neurotoxicity: revisited","author":"Nigam","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2021091310552297300_ref7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/00063198-200111000-00013","article-title":"The clinical use of colistin in patients with cystic fibrosis","volume":"7","author":"Beringer","year":"2001","journal-title":"Curr Opin Pulm Med"},{"key":"2021091310552297300_ref8","doi-asserted-by":"crossref","DOI":"10.1177\/0897190020958246","article-title":"Safety of nebulized colistin solution as adjunctive treatment of lower respiratory tract infections","author":"Nadeem","year":"2020","journal-title":"J Pharm Pract"},{"key":"2021091310552297300_ref9","first-page":"549","article-title":"The mechanism of the neuromuscular blockade by antibiotics","volume":"146","author":"Kubikowski","year":"1963","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2021091310552297300_ref10","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/acschemneuro.8b00300","article-title":"Molecular mechanisms of neurotoxicity induced by polymyxins and chemoprevention","volume":"10","author":"Dai","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"2021091310552297300_ref11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ppul.24727","article-title":"Neurotoxicity in adult patients with cystic fibrosis using polymyxin B for acute pulmonary exacerbations","volume":"55","author":"Rekis","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2021091310552297300_ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/antibiotics8020040","article-title":"Can nebulised colistin therapy improve outcomes in critically ill children with multi-drug resistant gram-negative bacterial pneumonia?","volume":"8","author":"Aygun","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"2021091310552297300_ref13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11096-015-0077-4","article-title":"Colistin and neurotoxicity: recommendations for optimal use in cystic fibrosis patients","volume":"37","author":"Claus","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"2021091310552297300_ref14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/00912700122010537","article-title":"The pharmacokinetics of colistin in patients with cystic fibrosis","volume":"41","author":"Reed","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"2021091310552297300_ref15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.11150\/kansenshogakuzasshi1970.79.945","article-title":"Usefulness of parenteral colistin in treating of lower respiratory infection due to multidrug-resistant P. aeruginosa","volume":"79","author":"Endo","year":"2005","journal-title":"Kansenshogaku Zasshi"},{"key":"2021091310552297300_ref16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/dkg468","article-title":"Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis","volume":"52","author":"Li","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2021091310552297300_ref17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1183\/09031936.98.12030592","article-title":"Four years\u2019 experience of intravenous colomycin in an adult cystic fibrosis unit","volume":"12","author":"Ledson","year":"1998","journal-title":"Eur Respir J"},{"key":"2021091310552297300_ref18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1136\/thx.52.11.987","article-title":"Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis","volume":"52","author":"Conway","year":"1997","journal-title":"Thorax"},{"key":"2021091310552297300_ref19","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1177\/106002809102501101","article-title":"Toxicity of colistin in cystic fibrosis patients","volume":"25","author":"Bosso","year":"1991","journal-title":"DICP"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/9\/omab080\/40352681\/omab080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2021\/9\/omab080\/40352681\/omab080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:59:48Z","timestamp":1631530788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omab080\/6369256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omab080","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,9,1]]},"article-number":"omab080"}}